Egalet to Present Data from Abuse-Deterrence Studies at

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Egalet to Present Data from Abuse-Deterrence Studies at PAINWeek 2014 in Las Vegas

LAS VEGAS, Sept. 4, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq: EGLT ) ("Egalet") announces data presentations on Egalet-001, an abuse-deterrent, extended-release, oral morphine product candidate, at PAINWeek 2014 in Las Vegas September 2 to 6.

Egalet-001 was created using the Egalet Guardian™ Technology and was designed to resist common methods of abuse and specifically manipulation by injection, the leading method of abuse for morphine. This abuse-deterrent, extended-release morphine is in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.

"The data presented supports Egalet-001's strong abuse-deterrent characteristics, resisting not only common methods of physical and chemical manipulation, but also demonstrating the product candidate cannot be drawn into a syringe to be injected which would deter one of the most common methods of morphine abuse—abuse via injection," said Edward J. Cone, Ph.D., Principal Scientist, Drug Delivery and Abuse Deterrent Drug Products, Pinney Associates, who is presenting some of the data at PAINWeek 2014. "With the growing prescription medication abuse problem in the U.S., it is essential that we have prescription medicines, such as Egalet-001, with characteristics to deter abuse to help decrease the annual number of prescription drug-related deaths which currently surpass the number of deaths by motor vehicles."

The data being presented was from the Category 1 abuse deterrence studies for Egalet-001. The purpose of these studies was to perform a comprehensive, laboratory assessment of physical and chemical manipulation of Egalet-001 as compared to MS Contin® (morphine sulfate controlled-release) based on the Food and Drug Administration's (FDA) 2013 draft guidance. The results are being presented in two poster presentations today from 6:30 pm to 8:30 PDT, one by Dr. Cone and the other by Karsten Lindhardt, Ph.D., senior vice president research and development at Egalet.

Abstract Highlights

  • Egalet-001 demonstrated greater resistance to common forms of physical and chemical manipulation as compared to MS Contin;
  • Egalet-001 resisted crushing in order to swallow, snort or smoke, and dissolving in order to inject which is one of the most common methods of abuse of morphine-based products
  • Egalet-001 displayed extreme resistance to crushing and grinding with all household tools used in the study, whereas the comparator was easily converted to a fine powder;
  • Pre-treatment of Egalet-001 by thermal stressing or freezing did not alter its resistance to physical manipulation attempts
  • Egalet-001 tablets resisted all extraction attempts and maintained extended release characteristics throughout the studies; and
  • Extreme gelling of Egalet-001 occurred after exposure to all aqueous solvents, which indicates that Egalet-001 will not be injectable.

About Egalet-001

Egalet-001 was created using our Guardian™ Technology and was designed to resist common methods of abuse and specifically manipulation by injection, the leading method of abuse for morphine. In the U.S., Morphine is the most commonly prescribed extended-release opioid with 7.1 million prescriptions written for extended-release oral morphine in calendar year 2013 up from 5.8 million prescriptions written in 2009 according to IMS. With no abuse-deterrent, extended release morphine products currently available, if approved, Egalet-001 will address this unmet need. Egalet is conducting studies to establish Egalet-001's abuse-deterrent properties, with the goal of obtaining abuse-deterrent claims in the product label in accordance with the draft FDA Guidance titled "Abuse-Deterrent Opioids - Evaluation and Labeling." 

About Egalet

Egalet's mission is to help ensure access to effective medications for individuals living with chronic pain while protecting physicians, families and communities from the burden of abuse. Prescription opioid abuse has reached epidemic levels in the United States, with 6.8 million current prescription drug abusers and drug abuse is now the leading cause of accidental death in the United States. With the majority of opioids abused in the United States originating from a prescription and most often coming from a friend or family, a safeguard against the unexpected is needed. Egalet is committed to bringing peace of mind to the patients and physicians it serves by offering abuse-deterrent pain medications. Using the proprietary Guardian™ Technology the Company has a pipeline of clinical-stage, opioid-based product candidates that are specifically designed to deter abuse by physical and chemical manipulation. The Guardian Technology is customized to resist specific routes of abuse that often occur with the underlying active pharmaceutical ingredient. The Company's lead program, Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation, is in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. It was designed to resist common methods of abuse, including one of the most common routes for morphine via injection. With no abuse-deterrent formulations of morphine currently available, Egalet-001 which is in pivotal studies, if approved, could fill a significant unmet need in the marketplace. Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation, is in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. Egalet-002 was designed to resist common methods of abuse, including crushing and snorting the most common route of abuse for oxycodone. Egalet entered into a collaboration with Shionogi in November of 2013, to develop abuse-deterrent hydrocodone based products. Egalet's Guardian™ Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles. Egalet has a strong IP position of 58 granted patents and is continually enhancing its proprietary position. Visit www.egalet.com for more information.

Safe Harbor

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations, and are subject to known and unknown uncertainties and risks.  Actual results could differ materially from those discussed due to a number of factors, including, but not limited to: the success of our clinical trials; our ability to obtain regulatory approval of our product candidates; competitive factors; general market conditions; and other risks factors described in Egalet's filings with the United States Securities and Exchange Commission. Egalet assumes no obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by law.

Investor and Media Contact: BiotechComm E. Blair Clark-Schoeb Tel: 917-432-9275 Email:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SiteOne Joins S&P SmallCap 600 Amid KKR's Integer Buyout

Updated Category News Views 25

Changes on the SmallCap Horizon Starting off, SiteOne Landscape Supply (NYSE: SITE) is hopping onto the S&P SmallCap 600 bandwagon. This shift activates just as the market revs up on November 19, 2026. SiteOne is stepping in as Integer Holdings Corp. (NYSE: ITGR) makes its grand exit, a move prompted by a significant acquisition by KKR & Co. Inc. (NYSE: KKR). KKR’s...

Continue Reading
Lecanemab Shines in 5-Year Alzheimer's Study at CTAD

Updated Category News Views 19

Latest Lecanemab Results Turn Heads at CTAD 2026 The whispers buzzing out of the CTAD 2026 conference are about something promising for those in the trenches of Alzheimer's research: lecanemab. Yep, it's a name that's been bandied about before, and this time it's the long-term data doing the talking. The five-year results from Eisai and Biogen's lecanemab study are...

Continue Reading
Crocs to Present at Key Industry Conferences

Updated Category News Views 19

Crocs Set to Step into the Spotlight Alright, if there's one thing about Crocs, Inc. (NASDAQ: CROX) that never fails to surprise, it's how they constantly keep everyone on their toes. The iconic casual footwear brand with its whimsical, love-it-or-hate-it reputation is strapping in for not one but two hefty conferences. They've circled November 19 and December 1, 2026, on...

Continue Reading
Ainstein Expands Kansas Operations Amid Sensor Demand Surge

Updated Category News Views 16

Ainstein's Expansion Conquers New Heights in Radar Tech Ainstein just cranked open a whole new chapter right in the heart of Kansas. And believe me, it's not your average ribbon-cutting story. This shiny new facility in Lenexa is locked and loaded to roll out 44,000 radar sensors a year. It's part of a no-nonsense plan to keep up with soaring demand for their tech across...

Continue Reading
191 Schools Honored for Academic Growth Success

Updated Category News Views 80

Celebrating Educational Progress Nationwide In a world where numbers fly off the stock tickers and translate into dollar signs in some corner office, it's refreshingly humbling to find real gains being celebrated in the educational sector. Curriculum Associates has tipped their hat to 191 schools that have done something remarkable: they've pushed students to stretch...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 88

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 30

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading
Arbor Realty Trust Faces Securities Fraud Allegations

Updated Category News Views 5

Securities Lawsuit Against Arbor Realty Trust Looms Well, here we go again. Another day, another securities lawsuit hitting the headlines. This time it's Arbor Realty Trust (NYSE: ABR) getting caught in the crossfire, accused of pulling the wool over investors' eyes. Seems like 'truth in advertising' is just part of the PR playbook for some big shots. Understanding the...

Continue Reading
SwitchBot's Hub 4: A Step Toward a Connected Future

Updated Category News Views 37

Turning a House Into a Smart Home Haven Out of Tokyo and onto the world stage, SwitchBot's got something new cooking that might just shake up the smart home scene. They've launched the Hub 4, a gadget that's like the Swiss Army knife of home control. For those who like things simple, this is a one-hub-to-rule-them-all kind of deal. 101,000 Reasons to Notice Now, they...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 41

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading

Top 5 Most Recently Viewed Articles

Aura Minerals Inc. Successfully Issues New Brazilian Debentures

Updated Category News Views 55

Aura Minerals Inc. Successfully Secures Funding through Debenture Issuance Aura Minerals Inc. (TSX: ORA) has recently made waves in the financial sector by successfully concluding the public offering of its 2nd issuance of debentures. The company announced this development following previous communications made on several dates earlier this year, confirming the completion...

Continue Reading
Emerging Trends in Clinical Trials Matching Software Market

Updated Category News Views 266

Growth of the Clinical Trials Matching Software Market The landscape of clinical trials is continually evolving, with the clinical trials matching software market expected to reach an impressive USD 501.86 million. This expansion points to a noteworthy compound annual growth rate (CAGR) of 13.14% between 2025 and 2032. Significance of AI and EHR Integration Market...

Continue Reading
Greystone Housing Plans Earnings Call to Discuss Q1 Results

Updated Category News Views 155

Greystone Housing to Host Earnings Conference Call Greystone Housing Impact Investors LP (NYSE: GHI) has announced it will be hosting an important earnings conference call for investors. This event is set to take place on a Wednesday at 4:30 p.m. Eastern Time. The focus of the call will be on discussing the financial results from the first quarter of the year....

Continue Reading
Successful Toyota Dealership Sale in the Automotive Market

Updated Category News Views 864

Performance Brokerage Services Facilitates Dealership Transaction Performance Brokerage Services, a leader in dealership buy-sell activities, has announced the successful sale of Premier Toyota. The dealership changed ownership from Robert Fisher to Kevin Wuepper, showcasing the brokerage firm’s expertise in the automotive sector. The Journey of Premier Toyota Founded...

Continue Reading
Investigation Launched into Sealed Air Corporation's Shareholder Deal

Updated Category News Views 193

Understanding the Investigation of Sealed Air Corporation In recent news, the Ademi Firm has initiated a probe into Sealed Air Corporation (NYSE: SEE), focusing on their proposed transaction with CD&R. This investigation is crucial because it centers on possible violations of fiduciary duty and legal requirements by the company’s board. The goal is to ensure that...

Continue Reading